National Pension Service Raises Holdings in Abbott Laboratories $ABT

National Pension Service boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 3,565,794 shares of the healthcare product maker’s stock after purchasing an additional 97,016 shares during the period. National Pension Service’s holdings in Abbott Laboratories were worth $477,602,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the business. McKinley Carter Wealth Services Inc. increased its holdings in Abbott Laboratories by 3.6% in the third quarter. McKinley Carter Wealth Services Inc. now owns 22,095 shares of the healthcare product maker’s stock valued at $2,959,000 after buying an additional 763 shares in the last quarter. Winnow Wealth LLC raised its holdings in shares of Abbott Laboratories by 5,648.7% in the 3rd quarter. Winnow Wealth LLC now owns 6,611 shares of the healthcare product maker’s stock worth $886,000 after purchasing an additional 6,496 shares during the period. Cornerstone Wealth Management LLC raised its position in Abbott Laboratories by 2.3% in the third quarter. Cornerstone Wealth Management LLC now owns 16,665 shares of the healthcare product maker’s stock valued at $2,232,000 after purchasing an additional 374 shares during the period. Significant Wealth Partners LLC lifted its holdings in Abbott Laboratories by 1.6% in the 3rd quarter. Significant Wealth Partners LLC now owns 6,157 shares of the healthcare product maker’s stock worth $825,000 after buying an additional 98 shares in the last quarter. Finally, AlphaQuest LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at approximately $158,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 3.0%

Abbott Laboratories stock opened at $109.31 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The business has a 50 day moving average price of $122.77 and a two-hundred day moving average price of $127.49. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The stock has a market cap of $190.08 billion, a price-to-earnings ratio of 29.39, a price-to-earnings-growth ratio of 1.69 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the business posted $1.34 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date is Thursday, January 15th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is 67.74%.

Analyst Ratings Changes

Several brokerages recently issued reports on ABT. Jefferies Financial Group raised their price objective on Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. Benchmark initiated coverage on Abbott Laboratories in a research note on Friday, October 10th. They set a “buy” rating and a $145.00 target price for the company. Barclays increased their price target on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.75.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.